Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

Figures & data

Table 1 FCDT vs monotherapy or concomitant therapy with dorzolamide and/or timolol

Authors	Time point	Treatment	N	Baseline IOP (SD) (mmHg)	Treatment IOP (SD) (mmHg)	Change (SD)	% change (SD)
Boyle et al^Citation40	Month 3 trough	FCDT	114	27.8 (5.0)	20.1 (4.5)	–7.7 (4.2)	–27.4 (13.1)
		Dorzolamide	109	28.1 (4.7)	23.5 (4.2)	–4.6 (4.3)	–15.5 (13.5)
		Timolol	111	27.9 (4.6)	21.5 (4.0)	–6.4 (4.1)	–22.2 (12.5)
	Month 3 peak	FCDT	112	27.1 (4.3)	18.1 (3.8)	–9.0 (4.3)	–32.7 (12.9)
		Dorzolamide	109	27.3 (3.8)	21.8 (4.3)	–5.4 (3.6)	–19.8 (12.6)
		Timolol	110	27.3 (4.4)	21.0 (4.7)	–6.3 (4.7)	–22.6 (15.6)
Clineschmidt et al^Citation39	Month 3 trough	FCDT	102	25.5 (3.4)	22.7 (3.9)	–2.8 (3.4)	–10.6 (12.5)
		Dorzolamide	51	25.5 (3.8)	24.2 (5.1)	–1.4 (4.3)	–4.9 (16.7)
		Timolol	98	25.2 (3.1)	23.6 (4.3)	–1.7 (3.1)	–6.7 (11.9)
	Month 3 peak	FCDT	103	25.0 (3.9)	20.7 (4.5)	–4.4 (3.3)	–17.3 (12.9)
		Dorzolamide	51	24.7 (3.3)	22.7 (3.8)	–2.0 (4.1)	–7.4 (15.8)
		Timolol	95	24.3 (2.6)	22.8 (4.6)	–1.6 (3.7)	–6.6 (15.3)
Hutzelmann et al^Citation53	Month 3	FCDT	151	25.6 (3.1)	21.4 (4.1)	–4.2 (3.3)	–16.3 (12.5)
	Trough	D + T	148	25.3 (3.2)	21.1 (3.7)	–4.2 (3.1)	–16.3 (11.5)
		FCDT	151	24.7 (3.2)	19.4 (3.7)	–5.4 (3.1)	–21.6 (12.3)
	Month 3 peak	D + T	148	24.5 (3.2)	19.1 (3.5)	–5.4 (3.3)	–21.8 (11.9)
Strohmaier et al^Citation54	Month 3	FCDT	120	26.1 (3.0)	22.5 (4.1)	–3.6 (3.0)	–13.8 (11.1)
	Trough	D + T	121	26.1 (3.8)	22.0 (4.4)	–4.1 (3.7)	–15.5 (13.8)
		FCDT	119	25.1 (3.3)	20.1 (3.8)	–5.0 (3.5)	–19.7 (12.9)
	Month 3 peak	D + T	120	25.0 (3.7)	20.2 (4.2)	–4.9 (3.8)	–19.1 (14.4)
		FCDT	116	23.7 (3.9)	20.0 (3.9)	–3.7 (3.4)	–14.9 (13.2)

Abbreviations: FCDT, fixed combination dorzolamide–timolol; D, dorzolamide; T, timolol.

Table 2 FCDT vs other prostaglandin analogs

Authors	Time point	Treatment	Mean baseline IOP (SD) (mmHg)	Mean treatment IOP (SD) (mmHg)	P-value
Orzalesi et al^Citation45	Month 1	FCDT	22.6 (2.7)	16.9 (1.4)
		Latanoprost	22.6 (2.7)	16.7 (0.6)	>0.05
Fechtner et al^Citation69	Month 3 (study 1)	FCDT	26.1	18.9
		Latanoprost	25.6	18.4	>0.05
	Month 3 (study 2)	FCDT	25.3	17.4
		Latanoprost	24.7	17.5	>0.05
Konstas et al^Citation44	Week 6	FCDT	25.8 (1.4)	15.3 (2.0)
		Latanoprost	25.8 (1.4)	15.9 (2.3)	0.05
Konstas et al^Citation44 (pseudoexfoliation patients)	Month 2	FCDT	31.2 (6.5)	18.1 (3.0)
		Latanoprost	31.2 (6.5)	18.9 (4.1)	0.21
Susanna et al^Citation42	Month 2	FCDT	23.6 (3.3)	17.2 (3.1)
		Latanoprost	23.5 (2.8)	16.6 (3.0)	>0.05
Day et al^Citation50	Month 2	FCDT	24.8 (2.4)	18.1 (2.8)
		Bimatoprost	24.8 (2.4)	17.4 (2.9)	0.35
Ozturk et al^Citation46	Month 6	FCDT	24.1 (2.1)	17.6 (2.9)
		Bimatoprost	23.7 (2.0)	17.5 (2.3)	0.48
Coleman^Citation49	Month 3 (0800 h)	FCDT	24.8 (2.5)	19.8
		Bimatoprost	25.0 (2.5)	18.2	<0.001

Abbreviation: FCDT, fixed combination dorzolamide–timolol.

Table 3 A, B FCDT versus other combination antiglaucoma drugs

A
Authors	Time point	Treatment	Mean baseline IOP (SD) (mmHg)	Mean treatment IOP (SD) (mmHg)	Treatment difference	P-value
Arcieri et al^Citation58	Month 1	FCDT	22.9 (1.6)	15.4 (2.1)	0.4	0.43
		FCBT	22.9 (1.6)	15.0 (2.1)
Konstas et al^Citation63	Month 2	FCDT	20.2 (1.9)	17.0 (2.0)	0.27	0.36
		FCLT	20.1 (2.0)	17.3 (2.2)
Shin et al^Citation62	Month 3	FCDT	27.5 (3.1)	19.1 (3.3)	0.6	0.005
		FCLT	27.9 (3.6)	18.5 (2.9)
Kalzuny et al^Citation61	Week 6 trough	FCDT	23.4 (2.3)	18.0 (2.2)	0.6	0.22
		FCPT		17.4 (2.0)
	Diurnal curve	FCDT	22.3 (3.7)	18.1 (2.2)	1.4	0.0007
		FCPT		16.7 (1.9)
Day et al^Citation52	Week 6 trough	FCDT	24.3 (3.0)	20.1 (4.5)		0.55
		T + U		20.1 (4.5)
	Diurnal curve	FCDT	23.4 (3.2)	19.8 (4.1)		0.63
		T + U		19.8 (4.1)
Teus et al^Citation67	Week 6	FCDT	26.1 (0.18)	17.7 (0.25)		0.002
		Tr + T	26 (0.18)	16.6 (0.26)	1.1
B
Zabriskie and Netland^Citation59	Month 3 (study 1)	FCDT	6.5	25.3
		B + L	9.0	33.9		0.044
	Month 3 (study 2)	FCDT	6.6	26.3
		B + L	9.1	33.4		0.047

Abbreviations: FCDT, fixed combination dorzolamide–timolol; FCBT, fixed combination brimonidine–timolol; FCPT, fixed combination pilocarpine; timolol; FCLT, fixed combination latanoprost–timolol; T + U, timolol + unoprostone; Tr + T, travoprost + timolol; B + L, brimonidine + latanoprost.

BoyleJEGhoshKGieserDKA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzo lamide-Timolol Study GroupOphthalmology1998105194519519787368

 PubMed Web of Science ®Google Scholar

ClineschmidtCMWilliamsRDSnyderEA randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study GroupOphthalmology199810519529599787369

 PubMed Web of Science ®Google Scholar

HutzelmannJOwensSSheddenAComparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study GroupBr J Ophthalmol199882124912539924327

 PubMed Web of Science ®Google Scholar

StrohmaierKSnyderEDuBinerHThe efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study GroupOphthalmology1998105193619449787367

 PubMed Web of Science ®Google Scholar

OrzalesiNRissettiLBottoliAThe effect of latanoprost, brimonidinee and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertensionArch Ophthalmol200312145345712695241

 PubMed Web of Science ®Google Scholar

FechtnerRDMcCarrollKALinesCREfficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studiesJ Ocul Pharmacol Ther20052124224915969642

 PubMed Web of Science ®Google Scholar

KonstasAGPapapanosPTersisITwenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combinationOphthalmology20031101357136012867391

 PubMed Web of Science ®Google Scholar

SusannaRJrSheuWPComparison of latanoprost with fixed combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin AmericaClin Ther20042675576815220019

 PubMed Web of Science ®Google Scholar

DayDGSharpeEDBeischelCJSafety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combinationEur J Ophthalmol20051533634215945001

 PubMed Web of Science ®Google Scholar

OzturkFErmisSInanUComparison of ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6 month studyActa Ophthalmol Scand200785808317244215

 PubMedGoogle Scholar

ColemanALLernerFBernsteinPA 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertensionOphthalmology20031102362236814644719

 PubMed Web of Science ®Google Scholar

ArcieriESPereiraACAAndreoEGVFixed combination brimonidinee-timolol (Combigan) versus fixed combination dorzolamide-timolol (Cosopt) each given twice daily to reduce intraocular pressure in subjects with glaucoma or ocular hypertension [abstract no. E434–169]Invest Ophthalmol Vis Sci200647

 Google Scholar

KonstasAGKozobolisVPLallosNDaytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%Eye2004181264126915218522

 PubMed Web of Science ®Google Scholar

ShinDHFeldmanRMSheuWPEfficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressureOphthalmology200411127628215019375

 PubMed Web of Science ®Google Scholar

KalzunyJSzaflikJCzechowicz-JanickaKTimolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open angle glaucoma or ocular hypertensive patientsActa Ophthalmol Scand20038134935412859261

 PubMedGoogle Scholar

DayDGSchacknowCJWandMTimolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open angle glaucoma or ocular hypertensionAm J Ophthalmol200313513814312566015

 PubMed Web of Science ®Google Scholar

TeusMAMigliorSLaganovskaGEfficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2009362963619997566

 PubMedGoogle Scholar

ZabriskieNNetlandPAComparison of brimonidinee/latanoprost and timolol/dorzolamide: two randomized, double masked, parallel clinical trialsAdv Ther2003209210012836809

 PubMed Web of Science ®Google Scholar